Development of influenza H7N9 virus like particle (VLP) vaccine: Homologous A/Anhui/1/2013 (H7N9) protection and heterologous A/chicken/Jalisco/CPA1/2012 (H7N3) cross-protection in vaccinated mice challenged with H7N9 virus

Smith, Gale; Flyer, David C.; Raghunandan, Rama; Liu, Ye; Wei, Ziping; Wu, Yingyun; Kpamegan, Eloi; Courbron, Denise; Fries, Louis; Glenn, Gregory M.

doi:10.1016/j.vaccine.2013.07.043

Cited by 105 publications

(104 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These results and recent reports from other groups show that there is substantial cross-reactivity between H7 strains in mice and humans (20,(36)(37)(38)(39) but to a much lesser extent in ferrets (24). This cross-reactivity is most likely induced by antibodies against antigenic site A, which is highly conserved in avian H7 isolates.…”

Section: Discussionsupporting

confidence: 79%

Divergent H7 Immunogens Offer Protection from H7N9 Virus Challenge

Krammer

Albrecht

Tan

et al. 2014

J Virol

View full text Add to dashboard Cite

The emergence of avian H7N9 viruses in humans in China has renewed concerns about influenza pandemics emerging from Asia. Vaccines are still the best countermeasure against emerging influenza virus infections, but the process from the identification of vaccine seed strains to the distribution of the final product can take several months. In the case of the 2009 H1N1 pandemic, a vaccine was not available before the first pandemic wave hit and therefore came too late to reduce influenza morbidity. H7 vaccines based on divergent isolates of the Eurasian and North American lineages have been tested in clinical trials, and seed strains and reagents are already available and can potentially be used initially to curtail influenza-induced disease until a more appropriately matched H7N9 vaccine is ready. In a challenge experiment in the mouse model, we assessed the efficacy of both inactivated virus and recombinant hemagglutinin vaccines made from seed strains that are divergent from H7N9 from each of the two major H7 lineages. Furthermore, we analyzed the cross-reactive responses of sera from human subjects vaccinated with heterologous North American and Eurasian lineage H7 vaccines to H7N9. Vaccinations with inactivated virus and recombinant hemagglutinin protein preparations from both lineages raised hemagglutination-inhibiting antibodies against H7N9 viruses and protected mice from stringent viral challenges. Similar cross-reactivity was observed in sera of human subjects from a clinical trial with a divergent H7 vaccine. Existing H7 vaccine candidates based on divergent strains could be used as a first line of defense against an H7N9 pandemic. In addition, this also suggests that H7N9 vaccines that are currently under development might be stockpiled and used for divergent avian H7 strains that emerge in the future. IMPORTANCESporadic human infections with H7N9 viruses started being reported in China in the early spring of 2013. Despite a significant drop in the number of infections during the summer months of 2013, an increased number of cases has already been reported for the 2013-2014 winter season. The high case fatality rate, the ability to bind to receptors in the human upper respiratory tract in combination with several family clusters, and the emergence of neuraminidase inhibitor-resistant variants that show no loss of pathogenicity and the ability to transmit in animal models have raised concerns about a potential pandemic and have spurred efforts to produce vaccine candidates. Here we show that antigen preparations from divergent H7 strains are able to induce protective immunity against H7N9 infection.

show abstract

Section: Discussionsupporting

confidence: 79%

Divergent H7 Immunogens Offer Protection from H7N9 Virus Challenge

Krammer

Albrecht

Tan

et al. 2014

J Virol

View full text Add to dashboard Cite

show abstract

“…The immunogenicity of Mong/119 might be due to the presence of epitopes for helper T cells that promote antibody responses of B cells (56). Thus, the vaccine prepared from the virus library is expected to be effective against the H7N9 virus emerging in humans (57)(58)(59).…”

Section: Discussionmentioning

confidence: 99%

Emergence of H7N9 Influenza A Virus Resistant to Neuraminidase Inhibitors in Nonhuman Primates

Itoh

Shichinohe

Nakayama

et al. 2015

Antimicrob Agents Chemother

View full text Add to dashboard Cite

viruses with low sensitivity to the NA inhibitors were detected was much higher than that of macaques in which variant H5N1 highly pathogenic influenza virus was detected after treatment with one of the NA inhibitors in our previous study. The virus with R289K in NA was reported in samples from human patients, whereas that with I219T in NA was identified for the first time in this study using macaques, though no variant H7N9 virus was reported in previous studies using mice. Therefore, the macaque model enables prediction of the frequency of emerging H7N9 virus resistant to NA inhibitors in vivo. Since H7N9 strains resistant to NA inhibitors might easily emerge compared to other influenza viruses, monitoring of the emergence of variants is required during treatment of H7N9 influenza virus infection with NA inhibitors.

show abstract

“…We recently showed that ferret antiserum against these H7 ca viruses had cross-reactivity to the H7N9 virus (30). The cross-reactivity between divergent H7 viruses was also reported for the inactivated virus, recombinant protein, or virus-like particle (VLP) vaccines studied in mice (31)(32)(33) or humans (34). Another Eurasian-lineage H7N3 LAIV reassortant with an alternative internal gene backbone was reported to induce cross-reactive antibodies to H7N9 (35), indicating that an H7 LAIV might be protective against a divergent H7 strain.…”

mentioning

confidence: 82%

Development of a High-Yield Live Attenuated H7N9 Influenza Virus Vaccine That Provides Protection against Homologous and Heterologous H7 Wild-Type Viruses in Ferrets

Chen

Baz

et al. 2014

J Virol

View full text Add to dashboard Cite

IMPORTANCEIn response to the recent avian H7N9 influenza virus infection in humans, we developed a live attenuated H7N9 influenza vaccine (LAIV) with two amino acid substitutions in the viral HA protein that improved vaccine yield by 10-fold in chicken embryonated eggs, the substrate for vaccine manufacture. The two amino acids also improved the antigen yield for inactivated H7N9 vaccines, demonstrating that this finding could great facilitate the efficiency of H7N9 vaccine manufacture. The candidate H7N9 LAIV was immunogenic and protected ferrets against homologous and heterologous wild-type H7 virus challenge, making it suitable for use in protecting humans from H7 infection.

show abstract

Development of influenza H7N9 virus like particle (VLP) vaccine: Homologous A/Anhui/1/2013 (H7N9) protection and heterologous A/chicken/Jalisco/CPA1/2012 (H7N3) cross-protection in vaccinated mice challenged with H7N9 virus

Cited by 105 publications

References 19 publications

Divergent H7 Immunogens Offer Protection from H7N9 Virus Challenge

Divergent H7 Immunogens Offer Protection from H7N9 Virus Challenge

Emergence of H7N9 Influenza A Virus Resistant to Neuraminidase Inhibitors in Nonhuman Primates

Development of a High-Yield Live Attenuated H7N9 Influenza Virus Vaccine That Provides Protection against Homologous and Heterologous H7 Wild-Type Viruses in Ferrets

Contact Info

Product

Resources

About